Citius Pharmaceuticals, Inc.
CTXR
$0.58
-$0.02-3.08%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -10.41% | -57.73% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -10.41% | -57.73% | |||
| Cost of Revenue | 49.53% | -58.32% | |||
| Gross Profit | -25.14% | -57.58% | |||
| SG&A Expenses | -67.00% | 201.76% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -64.20% | 159.42% | |||
| Operating Income | 67.15% | -260.82% | |||
| Income Before Tax | 57.56% | -210.43% | |||
| Income Tax Expenses | 53.59% | -187.51% | |||
| Earnings from Continuing Operations | 57.60% | -199.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -55.57% | 486.36% | |||
| Net Income | 58.26% | -158.26% | |||
| EBIT | 67.15% | -260.82% | |||
| EBITDA | -- | -279.83% | |||
| EPS Basic | 64.30% | -148.12% | |||
| Normalized Basic EPS | 76.20% | -179.71% | |||
| EPS Diluted | 64.30% | -148.12% | |||
| Normalized Diluted EPS | 76.20% | -179.71% | |||
| Average Basic Shares Outstanding | 16.95% | 4.10% | |||
| Average Diluted Shares Outstanding | 16.95% | 4.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||